

## FINANCIAL TEAR SHEET

### Corporate Profile

We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our collaborators – a novel product pipeline of central nervous system, or CNS, therapies to address areas of high unmet medical need, such as epilepsy, migraine, and pain.

### Stock Performance

#### XENE (Common Stock)

<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	<b>\$7.90</b>
<b>Change (%)</b>	▼ 0.35 (4.24%)
<b>Volume</b>	58,563
<b>52 Week Low</b>	\$2.10
<b>Market Cap</b>	\$116,920,551
<b>Rolling EPS</b>	-1.50
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	14,172,188



Data as of 06/19/18 4:00 p.m. ET

# Recent Press Releases & Upcoming Events

June 1, 2018 - [Xenon Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference](#)

There are currently no events scheduled.

May 15, 2018 - [Xenon Presents Positive XEN1101 TMS Pharmacodynamic Phase 1 Data at 14th Eilat Conference](#)

May 15, 2018 - [Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference](#)

## SEC Filings

Filing Date	Form
06/15/18	<a href="#">4</a>
06/13/18	<a href="#">8-K</a>
06/08/18	<a href="#">SC 13G/A</a>
06/05/18	<a href="#">4</a>

## Corporate Governance

[Simon Pimstone, MBChB, Ph.D., FRCPC](#)

[Ian Mortimer, MBA, CPA, CMA](#)

[Ernesto Aycardi, M.D.](#)

[Robin Sherrington, Ph.D.](#)

[James Empfield, Ph.D.](#)

[Charles Cohen, PhD](#)

[Jodi Regts, BA, MBA](#)

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)